Journal of Archives in Military Medicine

Published by: Kowsar

Monoclonal Antibody Consumption Pattern in a Sponsored Tertiary-Care Healthcare System in a Developing Country: A Five-Year Study From 2013 - 2017

Inam Danish Khan 1 , * , Anantharam Tejus 1 , HN Vidyullatha 2 , KS Rajmohan 1 , Anuradha Makkar 1 , Jadhav Amol 1 , Narayanan Subhramanian 1 , Pragyan Swagatika Panda 1 , Manisha Gupta 3 , Parwez Parwez 4 and Sikandar Hayat 5
Authors Information
1 Army College of Medical Sciences and Base Hospital, New Delhi, India
2 Raja Rajeshwari Dental College and Hospital, Bangalore, India
3 Sanjay Gandhi Post Graduate Institute, Lucknow, India
4 Institute of Human Behaviour and Allied Sciences, New Delhi, India
5 Lady Harding Medical College, New Delhi, India
Article information
  • Journal of Archives in Military Medicine: September 2018, 6 (3); e79185
  • Published Online: November 17, 2018
  • Article Type: Research Article
  • Received: May 17, 2018
  • Accepted: November 10, 2018
  • DOI: 10.5812/jamm.79185

To Cite: Khan I D, Tejus A, Vidyullatha H, Rajmohan K, Makkar A, et al. Monoclonal Antibody Consumption Pattern in a Sponsored Tertiary-Care Healthcare System in a Developing Country: A Five-Year Study From 2013 - 2017, J Arch Mil Med. 2018 ; 6(3):e79185. doi: 10.5812/jamm.79185.

Abstract
Copyright © 2018, Journal of Archives in Military Medicine. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Methods
3. Results
4. Discussion
Footnote
References
  • 1. Liu JK. The history of monoclonal antibody development - Progress, remaining challenges and future innovations. Ann Med Surg (Lond). 2014;3(4):113-6. doi: 10.1016/j.amsu.2014.09.001. [PubMed: 25568796]. [PubMed Central: PMC4284445].
  • 2. Elgundi Z, Reslan M, Cruz E, Sifniotis V, Kayser V. The state-of-play and future of antibody therapeutics. Adv Drug Deliv Rev. 2017;122:2-19. doi: 10.1016/j.addr.2016.11.004. [PubMed: 27916504].
  • 3. Ecker DM, Jones SD, Levine HL. The therapeutic monoclonal antibody market. MAbs. 2015;7(1):9-14. doi: 10.4161/19420862.2015.989042. [PubMed: 25529996]. [PubMed Central: PMC4622599].
  • 4. Yamada T. Therapeutic monoclonal antibodies. Keio J Med. 2011;60(2):37-46. doi: 10.2302/kjm.60.37. [PubMed: 21720199].
  • 5. Landolina N, Levi-Schaffer F. Monoclonal antibodies: The new magic bullets for allergy: IUPHAR Review 17. Br J Pharmacol. 2016;173(5):793-803. doi: 10.1111/bph.13396. [PubMed: 26620589]. [PubMed Central: PMC4761089].
  • 6. Tomita M, Tsumoto K. Hybridoma technologies for antibody production. Immunotherapy. 2011;3(3):371-80. doi: 10.2217/imt.11.4. [PubMed: 21395379].
  • 7. Smith SA, Crowe JE, Jr. Use of human hybridoma technology to isolate human monoclonal antibodies. Microbiol Spectr. 2015;3(1):AID-27-2014. doi: 10.1128/microbiolspec.AID-0027-2014. [PubMed: 26104564].
  • 8. Das S, Sehgal VK. Monoclonal antibodies and its impact on modern health services- A review. Int J Pharmacolog Res. 2017;7(8):154-9. doi: 10.7439/ijpr.
  • 9. Ponsel D, Neugebauer J, Ladetzki-Baehs K, Tissot K. High affinity, developability and functional size: The holy grail of combinatorial antibody library generation. Molecules. 2011;16(5):3675-700. doi: 10.3390/molecules16053675. [PubMed: 21540796].
  • 10. Koussoroplis SJ, Paulissen G, Tyteca D, Goldansaz H. PEGylation of antibody fragments greatly increases their local residence time following delivery to the respiratory tract. J Control Release. 2014;187:91-100. doi: 10.1016/j.jconrel.2014.05.021. [PubMed: 24845126].
  • 11. Saxena A, Wu D. Advances in therapeutic Fc engineering - modulation of IgG-associated effector functions and serum half-life. Front Immunol. 2016;7:580. doi: 10.3389/fimmu.2016.00580. [PubMed: 28018347]. [PubMed Central: PMC5149539].
  • 12. Chiu ML, Gilliland GL. Engineering antibody therapeutics. Curr Opin Struct Biol. 2016;38:163-73. doi: 10.1016/j.sbi.2016.07.012. [PubMed: 27525816].
  • 13. Jiang XR, Song A, Bergelson S, Arroll T, Parekh B, May K, et al. Advances in the assessment and control of the effector functions of therapeutic antibodies. Nat Rev Drug Discov. 2011;10(2):101-11. doi: 10.1038/nrd3365. [PubMed: 21283105].
  • 14. Paggiaro P, Bacci E. Montelukast in asthma: A review of its efficacy and place in therapy. Ther Adv Chronic Dis. 2011;2(1):47-58. doi: 10.1177/2040622310383343. [PubMed: 23251741]. [PubMed Central: PMC3513871].
  • 15. Thomson NC, Chaudhuri R. Omalizumab: Clinical use for the management of asthma. Clin Med Insights Circ Respir Pulm Med. 2012;6:27-40. doi: 10.4137/CCRPM.S7793. [PubMed: 22745565]. [PubMed Central: PMC3382304].
  • 16. Thomson NC. Recent advances in the treatment and management of asthma. Prescriber. 2015;26(18):17-24. doi: 10.1002/psb.1385.
  • 17. Singh S, Singh N. Current trends of management of respiratory diseases by pulmonologists: Results of national conference of pulmonary disease - 2015 survey. Lung India. 2017;34(1):13-8. doi: 10.4103/0970-2113.197093. [PubMed: 28144054]. [PubMed Central: PMC5234191].
  • 18. Morishima T, Ikai H, Imanaka Y. Cost-effectiveness analysis of omalizumab for the treatment of severe asthma in Japan and the value of responder prediction methods based on a multinational trial. Value Health Reg Issues. 2013;2(1):29-36. doi: 10.1016/j.vhri.2013.01.007. [PubMed: 29702848].
  • 19. Vennera Mdel C, Valero A, Uria E, Forne C, Picado C. Cost-effectiveness analysis of omalizumab for the treatment of severe persistent asthma in real clinical practice in Spain. Clin Drug Investig. 2016;36(7):567-78. doi: 10.1007/s40261-016-0402-2. [PubMed: 27142072].
  • 20. Kumar D, Arya V, Kaur R, Bhat ZA, Gupta VK, Kumar V. A review of immunomodulators in the Indian traditional health care system. J Microbiol Immunol Infect. 2012;45(3):165-84. doi: 10.1016/j.jmii.2011.09.030. [PubMed: 22154993].
  • 21. Joshi SR. Diabetes care in India. Ann Glob Health. 2015;81(6):830-8. doi: 10.1016/j.aogh.2016.01.002. [PubMed: 27108150].
  • 22. Khan ID, Sahni AK. Bacterial infections and emerging resistance in renal transplant recipients. Bangladesh J Med Sci. 2014;14(1):14-21. doi: 10.3329/bjms.v14i1.16306.
  • 23. Khan ID, Dogra PM, Ramphal SK, Khan S, Konar J, Palit A, et al. Polymicrobial infections in a teenaged renal transplant recipient. J Basic Clin Med. 2015;4(1):37-9.
  • 24. Khan ID, Sahni AK, Bharadwaj R, Lall M, Jindal AK, Sashindran VK. Emerging organisms in a tertiary healthcare set up. Med J Armed Forces India. 2014;70(2):120-8. doi: 10.1016/j.mjafi.2013.09.005. [PubMed: 24843199]. [PubMed Central: PMC4017190].
  • 25. Danish Khan I, Mohan Gupta R, Sen S, Rajmohan KS, Kumar Jindal A, Makkar A, et al. Emerging antimicrobial resistance and evolving healthcare: Dangerous crossroads for the community and the military. J Arch Milit Med. 2017;(In Pre).
  • 26. Jindal AK, Pandya K, Khan ID. Antimicrobial resistance: A public health challenge. Med J Armed Forces India. 2015;71(2):178-81. doi: 10.1016/j.mjafi.2014.04.011. [PubMed: 25859082]. [PubMed Central: PMC4388962].
  • 27. Khan ID, Lall M, Sen S, Ninawe SM, Chandola P. Multiresistant Elizabethkingia meningoseptica infections in tertiary care. Med J Armed Forces India. 2015;71(3):282-6. doi: 10.1016/j.mjafi.2014.02.002. [PubMed: 26288498]. [PubMed Central: PMC4534552].
  • 28. Khan ID, Sati A, Arif S, Mehdi I, Bhatt P, Jain V, et al. Streptococcus mitis/oralis corneal ulcer after corneal transplantation. J Basic Clin Med. 2016;5(1):8-10.
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments